At the 20th Congress of the European Hematology Association (EHA), Sagar Lonial, MD, of the Winship Cancer Institute, Emory University, Atlanta, GA, reviews the development of immunotherapy using monoclonal antibodies (mAbs) for the treatment of patients multiple myeloma. He focuses on the basic and clinical aspects of the emerging and promising novel mAbs, daratumumab, which targets CD38, and elotuzumab, which targets signaling lymphocytic activation molecule-F7 (SLAMF7).
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates